After-Hours Movers 11/20: (XXII) (NUAN) (TIF) Higher; (OPTN) (LZB) (CUB) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
SunTrust Reiterates Buy Rating on Uber Inc. (UBER) Following 3Q and IPO Lock-Up Expiration
November 22, 2019 7:34 AM ESTSunTrust analyst Youssef Squali reiterated a Buy rating and $56.00 price target on Uber Inc. (NYSE: UBER) following the company's 3Q and IPO lock-up expiration.
Squali believes UBER has likely bottomed out, with the new Rides profitability disclosure providing valuation support. SunTrust... More
Molecular Templates (MTEM) Prices 6M Share Common Offering at $8/Sh
November 21, 2019 7:05 AM ESTMolecular Templates, Inc. (NASDAQ: MTEM) today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holders option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible preferred stock to be sold in the offering are being... More
Karuna Therapeutics Inc. (KRTX) Prices 2.6M Share Offering at $96/Sh
November 21, 2019 5:48 AM ESTKaruna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the pricing of its previously announced underwritten public offering... More
